Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose <i>BRCA1/2</i> mutations are well-known risk factors for breast and ovarian cancers in women. Risk-reducing salpingo-oophorectomy (RRSO) is the standard treatment for preventing ovarian cancer with <i>BRCA</i> mutations. Postmenopausal syndrome (symptoms after RRSO can be alleviated by hormone replacement therapy (HRT); however, the use of HRT in carriers of <i>BRCA</i> mutations has been controversial because of the concern that HRT increases the risk of breast cancer. This study aimed to evaluate the effects of HRT in <i>BRCA</i> mutation carriers who underwent RRSO.Materials and Methods A total of 151 carriers, who underwent RRSO between 2013 and 2020 after the diagnosis of <i>BRCA1</i> or <i>BRCA2</i> mutations were selected and followed up for a median of 3.03 years. Patients were divided into two groups: those who received HRT after RRSO (n=33) and those who did not (n=118). We compared the incidence of breast cancer over time between these two groups.Results There was no significant difference in the incidence of breast cancer between women who received HRT and those who did not (p=0.229). Multivariate logistic regression analysis, adjusted for age and parity revealed no significant difference in the risk of breast cancer between these two groups (hazard ratio, 0.312; 95% confidence interval, 0.039 to 2.480; p=0.278).Conclusion In this study, we found no relationship between post-RRSO HRT and breast cancer in the population with <i>BRCA</i> mutations. Therefore, healthcare providers may consider the alleviation of symptoms of postmenopausal syndrome through HRT in patients who underwent RRSO.
Abstract
Purpose BRCA1/2 mutations are well-known risk factors for breast and ovarian cancers in women. Risk-reducing salpingo-oophorectomy (RRSO) is the standard treatment for preventing ovarian cancer with BRCA mutations. Postmenopausal syndrome (symptoms after RRSO can be alleviated by hormone replacement therapy (HRT); however, the use of HRT in carriers of BRCA mutations has been controversial because of the concern that HRT increases the risk of breast cancer. This study aimed to evaluate the effects of HRT in BRCA mutation carriers who underwent RRSO. Materials and Methods A total of 151 carriers, who underwent RRSO between 2013 and 2020 after the diagnosis of BRCA1 or BRCA2 mutations were selected and followed up for a median of 3.03 years. Patients were divided into two groups: those who recei-ved HRT after RRSO (n=33) and those who did not (n=118). We compared the incidence of breast cancer over time between these two groups. Results There was no significant difference in the incidence of breast cancer between women who received HRT and those who did not (p=0.229). Multivariate logistic regression analysis, adjusted for age and parity revealed no significant difference in the risk of breast cancer between these two groups (hazard ratio, 0.312; 95% confidence interval, 0.039 to 2.480; p=0.278). Conclusion In this study, we found no relationship between post-RRSO HRT and breast cancer in the population with BRCA mutations. Therefore, healthcare providers may consider the alleviation of symptoms of postmenopausal syndrome through HRT in pati-ents who underwent RRSO.
참고문헌 (22)
- Miki Y, "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1", Science, 266, pp.66~71 (1994)
- Ford D, "Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium", Lancet, 343, pp.692~695 (1994)
- Daly MB, "NCCN guidelines insights : genetic", familial high-risk assessment : breast and ovarian, version 2. 2017, 2017, pp.15, 9~20
- Gallicchio L, "Type of menopause, patterns of hormone therapy use, and hot flashes", Fertil Steril, 85, pp.1432~1440 (2006)
- Madalinska JB, "Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovar ian cancer", J Clin Oncol, 23, pp.6890~6898 (2005)
- Finch A, "The impact of prophylactic salpingo-oophorecto my on menopausal symptoms and sexual function in women who carry a BRCA mutation", Gynecol Oncol, 121, pp.163~168 (2011)
- Lobo RA, "Surgical menopause and cardiovascular risks", Men opause, 14, pp.562~566 (2007)
- Yoshida T, "Impact of surgical menopause on lipid and bone metabolism", Climacteric, 14, pp.445~452 (2011)
- Michaelson-Cohen R, "Breast cancer risk and hor mone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy", Eur J Cancer, 148, pp.95102~ (2021)
- Rebbeck TR, "Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers : the PROSE Study Group", J Clin Oncol, 23, pp.7804~7810 (2005)
- Kotsopoulos J, "Hormone replacement therapy after oophorec tomy and breast cancer risk among BRCA1 mutation carriers", JAMA Oncol, 4, pp.1059~1065 (2018)
- Kim H, "Distribution of BRCA1 and BRCA2 muta tions in Asian patients with breast cancer", J Breast Cancer, 16, pp.357~365 (2013)
- Kurian AW, "BRCA1 and BRCA2 mutations across race and ethnicity : distribution and clinical implications", Curr Opin Obstet Gynecol, 22, pp.72~78 (2010)
- Haffty BG, "Breast cancer in young women(YBC) : prevalence of BRCA1", 2 mutations and risk of secondary malignancies across diverse racial groups, 2009, pp.20, 1653~1659
- Li CI, "Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older", Cancer Epidemiol Biomarkers Prev, 11, pp.601~607 (2002)
- Kim HA, "The epidemiology of total knee replacement in South Korea : national registry data", Rheumatology(Oxford), 47, pp.88~91 (2008)
- Eisen A, "Hormone therapy and the risk of breast cancer in BRCA1mutation carriers", J Natl Cancer Inst, 100, pp.1361~1367 (2008)
- Kotsopoulos J, "Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation car riers : a case-control study", Breast Cancer Res Treat, 155, pp.365~373 (2016)
- Finch AP, "Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation", J Clin Oncol, 32, pp.1547~1553 (2014)
- Terra L, "Sexual functioning more than 15 years after premenopausal risk reducing salpingo-oophorectomy", Am J Obstet Gynecol, 228, pp.440~ (2023)
- Stan DL, "Challenging and complex decisions in the management of the BRCA mutation carrier", J Womens Health(Larchmt), 22, pp.825~834 (2013)
- Gordhandas S, "Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits", Gynecol Oncol, 153, pp.192~200 (2019)